Scottish National Burden of Disease, Injuries and Risk Factors study:

Slides:



Advertisements
Similar presentations
Ananda Allan Senior Health Intelligence Analyst ‘The Quality Outcomes Framework (QOF): Can it be used for more than just paying GPs?’ Ananda Allan Senior.
Advertisements

Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
The role of economic modelling – a brief introduction Francis Ruiz NICE International © NICE 2014.
EXPECTED OUTCOMES The study will provide information on the impact of tobacco use on health from epidemiological, social and economic perspectives in relation.
Global Burden of Disease
The Impact of Co-morbidity 2 nd ACHRF Auckland, New Zealand 8 November 2012 Dr John Wren Principal Research Advisor ACC Dr Barry Gribben CBG Health Research.
Introduction to Public Health January 29,
Are the results valid? Was the validity of the included studies appraised?
Background Information : Projected prevalence of arthritis is expected to increase from 2.9 million to 6.5 million Canadians, a rise of 124% (Badley.
Health Status of Australian Adults. The health status of Australians is recognised as good and is continually improving. The life expectancy for males.
Chronic disease and its impact on disability and the need for LTC Carol Jagger Experts' Seminar on Ageing and Long-Term Care Needs 20 May 2011.
Measuring Output from Primary Medical Care, with Quality Adjustment Workshop on measuring Education and Health Volume Output OECD, Paris 6-7 June 2007.
Evidence-Based Medicine 3 More Knowledge and Skills for Critical Reading Karen E. Schetzina, MD, MPH.
Comorbidities and Diabetes Care – Impact on Treatment Strategies Dr. Joel Rodriguez-Saldana Multidisciplinary Diabetes Centres Mexico.
7 th Task Force on Health Expectancies Meeting Luxembourg, 2 December 2008 Dr. Enrique Loyola Health Intelligence Service Summary measures in public health.
Chronic Disease Cost Calculator 1:00 p.m.-2:30 p.m. ET Friday, May 1, 2009 Diane Orenstein, Ph.D. Division for Heart Disease and Stroke Prevention, CDC.
Introduction to Disease Prevalence modelling Day 6 23 rd September 2009 James Hollinshead Paul Fryers Ben Kearns.
CROSS SECTIONAL STUDIES
Heart failure and comorbidities
Quality and Outcomes Framework The national Quality and Outcomes Framework (QOF) was introduced as part of the new General Medical Services (GMS) contract.
Table 1. Methodological Evaluation of Observational Research (MORE) – observational studies of incidence or prevalence of chronic diseases Tatyana Shamliyan.
Alcohol-related mortality in European countries II Working Meeting on Adult Premature Mortality in European Union Warsaw, October 2006.
Summary Measures of Population Health Topics in Public Health April Sung-Il Cho.
Challenges to the Epidemiology of Aging: The REasons for Geographic And Racial Differences in Stroke Study George Howard, DrPH UAB School of Public Health.
Epidemiological Methods Duanping Liao, MD, Ph.D Professor and Vice Chair for Research Chief, Division of Epidemiology Department of Public Health Sciences.
Global burden of disease study : Past, present, and future
CROSS SECTIONAL STUDIES
Instructional Objectives:
for Overall Prognosis Workshop Cochrane Colloquium, Seoul
National Burden of Disease, Injuries
The Impact of Chronic Disease on a Future NHI
WHO DALY calculations Colin Mathers Coordinator, Mortality and Health Analysis Unit World Health Organization, Geneva Burden of disease methodological.
Tracking US healthcare spending;
Jürgen C Schmidt, Deputy Head, Public Health Data Science
Global burden of diseases
National Burden of Disease, Injuries
Wifi Network Name: RSE Guest Password: RSE
The Importance of Adequately Powered Studies
The Changing Story of Cancer
Colin Fischbacher Information Services Division (ISD)
Association between Systolic Blood Pressure
Greater Manchester Health & Social Care Partnership
Burden of Disease and the Netherlands
Experimental Design, Data collection, and sampling Techniques
Evaluating Policies in Cardiovascular Medicine
Burden of Disease and the Netherlands
The Impact of Chronic Disease on a Future NHI
JANPA FINAL CONFERENCE
Bronx Community Health Dashboard: Maternal and Child Health Last Updated: 1/31/2018 See last slide for more information about this project.
NAPLEX preparation: Biostatistics
Multimorbidity: prevention and management
Prevalence, Pattern and Correlates of Multimorbidity in
S1316 analysis details Garnet Anderson Katie Arnold
Dr. Muhammad Ajmal Zahid Chairman, Department of Psychiatry,
Marseille March 2017 WP2 Archana Singh-Manoux AURORE FAYOSSE.
Nuzhat Ali, National Lead MSK Health
MPH thesis - Tal Sharrock BODE3 University of Otago, Wellington
Measures of Disease Occurrence
Alcohol, Other Drugs, and Health: Current Evidence
Presented by Hedayet ullah Roll: , Reg: Department of Microbiology Jessore university of science & technology Disease Prevalence at Jessore.
Analytics – Statistical Approaches
Advancing the Science of Transformation in Integrated Primary Care: Informing Options for Scaling-up Innovation   Session 3: Addressing health equity and.
Treated Chronic Disease Cost in MN: A Look Back & a Look Forward
CROSS SECTIONAL STUDIES
Asthma, a chronic inflammatory disorder of the airways, is one of the more prevalent chronic conditions in Canada.1 According to the 2009/10 Canadian Community.
Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.
Adam J. O’Shay and T. N. Krishnamurti FSU Meteorology 8 February 2001
ANZDATA: Vascular Access
Tools to support development of interventions Soili Larkin & Mohammed Vaqar Public Health England West Midlands.
Presentation transcript:

Scottish National Burden of Disease, Injuries and Risk Factors study: Burden of Diseases Technical Workshop Edinburgh September 2016 Scottish National Burden of Disease, Injuries and Risk Factors study: Comorbidity correction Ian Grant Scottish Burden of Disease Study Project Team ScotPHO colloboration, Information and Services Division June 2016

Comorbidity in GBD GBD’s focus on correcting the estimates of cause-specific YLDs and total YLD for the biasing influence of comorbidity, rather than on analysing patterns of comorbidity per se. Models comorbidity in a large micro-simulated population and uses this to adjust disability weights in the final estimates - wherever possible, inputs to the micro-simulation for each country, age, sex, year group will be at the level of health sequelae - places no upper limit on the number of comorbid conditions - micro-simulation process repeated (for each country-age-sex- year) 1000 times 1st bullet The bias correction was achieved through microsimulation-based adjustments to the disability weights 2nd bullet last sub- bullet - so as to generate uncertainty in the prevalences and disability weights into comorbidity estimates

Comorbidity in GBD Model comorbidity assuming independent multiplicative model (i.e. probability of experiencing a combination of sequelae is simply the product of the probabilities of experiencing each of the constituent sequelae). Independent vs. Dependent comorbidity (i.e. diseases may ‘cluster’ because of common risk factors, or because one disease is itself a risk factor for other diseases. GBD tested independence assumption using US Medical Expenditure Panel Survey data which suggest that error in the magnitude of YLDs from using the independence assumption is minimal (Murray et al 2012) In New Zealand, reductions in overall YLD for dependent comorbidity beyond that required for adjustment due to independent comorbidity were small, although they did increase slightly with age (New Zealand Ministry of Health 2012) 1st bullet i.e. diseases (or health states) are independently distributed 2nd bullet – New Zealand used large population health surveys from New Zealand and from Canada to estimate dependent comorbidity for major chronic diseases. At most, in older people, failure to adjust for dependent (as opposed to independent) comorbidity will lead to underestimation of the YLD comorbidity adjustment by no more than 8%, according to our study

SBoD comorbidity process Broadly following the GBD’s methodological framework when adjusting our baseline (or default) estimates of YLDs for comorbidity bias i.e. Applying the multiplicative independence model : to Scottish estimates of individual disease and injury prevalences, to estimate prevalences for comorbidity, to the GBD disability weights / health losses for individual diseases and injuries, to estimate weights for comorbidity.   Broadly following the GBD’s methodological framework when adjusting our baseline (or default) estimates of YLDs for comorbidity bias. Apply the multiplicative independence model ie Assuming no correlation between diseases

SBoD comorbidity simulation algorithm Work with a synthetic population of size n, with the same age group and sex, and assume to be alive at the same calendar year. 2. For each individual i in a synthetic population set: (a) Assign him/her a number of co-morbidities Ci based on the probability distribution of the number of comorbidities (b) Repeat until the person has been assigned Ci different co-morbidities (i) Choose a disease sequela d based on a probability distribution RD (ii) Decide if the person has the disease d based on the probability of having such disease (point prevalence for the population subgroup) (iii) If the person has the disease: - Remove disease sequela from the list and update probability distribution RD Update number of comorbidities assigned to the person

SBOD Simulation algorithm (cont) (c) Once the person has been assigned Ci co-morbidities, work out the total co-morbidity adjusted disability weight for the simulant (d) And the disability weight attributable to each sequela for the simulant 4. Once all individuals have been done work out the YLD Rate for disease sequela k

SBoD Comorbidity process Not a full population simulation i.e. simulated population is 200 000 run the simulation ~1000 times. requires more than 1 year of computer power, that is 20 age groups x 1000 simulations x 40 min per simulation = 800 000 min = 555 days Or is it enough simulating 2000 people, 1000 times? Take into account probability distribution of the number of co- morbidities by age – with a limit on number of comorbidities (by age group)

Number of chronic disorders by age group The impact of age in the number of co morbidities is substantial Source: Barnet et al, 2012 Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study

SBOD: impact of comorbidity correction Disease YLD comorbidity adjusted YLD % change Neck and low back pain 44,373 48,184 8 Other musculoskeletal disorders 37,734 41,104 Oral disorders 29,641 31,556 6 Inflammatory bowel disease 29,090 32,476 10 Sense organ diseases 20,831 22,447 7 Migraine 19,632 22,315 12 Depression 19,090 21,123 Diabetes mellitus 18,096 19,639 Ischemic heart disease 16,880 18,309 Anxiety disorders 16,041 17,536 9 Results so far from simulation run only on 1000 individuals

SBOD supplementary analyses of comorbidity prevalences Consider whether and how best to exploit the potential of the Scottish evidence: Estimating the prevalence of comorbidities, to the depth of two or three co-present conditions. Assessing the degree to which the comorbidity prevalences observed in AHS and IHS conform to or depart from the multiplicative independence model. Making a broad assessment of the degree to which the overall adjustment of YLDs for comorbidity bias might be affected Using EHRS to calculate prevalence, we now a have a huge dataset which allows us to calculate YLD considering the actual co-morbidities suffered by the hospitalised population. Quick win : Could use, for instance, diseases correlation matrix in the long term conditions report. Or we could create our own correlation matrix, based on all (hospitalised) patient records

Number of co-existing conditions Analyses based on primary care data Interpretation: Of all people listed as having CHD, 8% have only CHD, 26% have CHD plus one other condition and 67% have CHD plus 2 or more other conditions (based on consultations within the same year).   Source: Measuring Long-Term Conditions in Scotland, Information Services Division, Edinburgh 2008 https://www.isdscotland.org/Health-Topics/Hospital-Care/Diagnoses/2008_08_14_LTC_full_report.pdf

Common combinations of conditions Analyses based on primary care data Interpretation: 4% of people with Asthma also have diabetes. 39% of people who have suffered a stroke also have hypertension   Source: Measuring Long-Term Conditions in Scotland, Information Services Division, Edinburgh 2008 https://www.isdscotland.org/Health-Topics/Hospital-Care/Diagnoses/2008_08_14_LTC_full_report.pdf

Discussion Comorbidity Comorbidity adjustment by means of a simulation presents multiple challenges, for instance: which co-morbidities and how many of them are assigned to a person; how the disability weights are combined. GBD methodology presents a solution to these questions, but is that the best methodology possible? How can data rich countries use their information to improve the comorbidity adjustment? Comorbidity